A futile metabolic cycle activated in adipocytes by antidiabetic agents
- PMID: 12357248
- DOI: 10.1038/nm780
A futile metabolic cycle activated in adipocytes by antidiabetic agents
Abstract
Thiazolidinediones (TZDs) are effective therapies for type 2 diabetes, which has reached epidemic proportions in industrialized societies. TZD treatment reduces circulating free fatty acids (FFAs), which oppose insulin actions in skeletal muscle and other insulin target tissues. Here we report that TZDs, acting as ligands for the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-gamma, markedly induce adipocyte glycerol kinase (GyK) gene expression. This is surprising, as standard textbooks indicate that adipocytes lack GyK and thereby avoid futile cycles of triglyceride breakdown and resynthesis from glycerol and FFAs. By inducing GyK, TZDs markedly stimulate glycerol incorporation into triglyceride and reduce FFA secretion from adipocytes. The 'futile' fuel cycle resulting from expression of GyK in adipocytes is thus a novel mechanism contributing to reduced FFA levels and perhaps insulin sensitization by antidiabetic therapies.
Comment in
-
A "futile cycle" induced by thiazolidinediones in human adipose tissue?Nat Med. 2003 Jul;9(7):811-2; author reply 812. doi: 10.1038/nm0703-811. Nat Med. 2003. PMID: 12835685 Clinical Trial. No abstract available.
Similar articles
-
Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells.J Biol Chem. 2003 May 23;278(21):18785-90. doi: 10.1074/jbc.M206999200. Epub 2003 Mar 18. J Biol Chem. 2003. PMID: 12644461
-
BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones.Diabetes. 1998 Apr;47(4):691-5. doi: 10.2337/diabetes.47.4.691. Diabetes. 1998. PMID: 9568706
-
A "futile cycle" induced by thiazolidinediones in human adipose tissue?Nat Med. 2003 Jul;9(7):811-2; author reply 812. doi: 10.1038/nm0703-811. Nat Med. 2003. PMID: 12835685 Clinical Trial. No abstract available.
-
[Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].Ann Endocrinol (Paris). 2002 Dec;63(6 Pt 1):511-23. Ann Endocrinol (Paris). 2002. PMID: 12527853 Review. French.
-
Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.Methods Find Exp Clin Pharmacol. 2002 Oct;24(8):515-23. doi: 10.1358/mf.2002.24.8.705072. Methods Find Exp Clin Pharmacol. 2002. PMID: 12500431 Review.
Cited by
-
Modulation of the transcriptional activity of peroxisome proliferator-activated receptor gamma by protein-protein interactions and post-translational modifications.Yonsei Med J. 2013 May 1;54(3):545-59. doi: 10.3349/ymj.2013.54.3.545. Yonsei Med J. 2013. PMID: 23549795 Free PMC article. Review.
-
Adipose Tissue Remodeling in Pathophysiology.Annu Rev Pathol. 2023 Jan 24;18:71-93. doi: 10.1146/annurev-pathol-042220-023633. Epub 2022 Sep 7. Annu Rev Pathol. 2023. PMID: 36070562 Free PMC article. Review.
-
Aquaporin 7 deficiency is associated with development of obesity through activation of adipose glycerol kinase.Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10993-8. doi: 10.1073/pnas.0503291102. Epub 2005 Jul 11. Proc Natl Acad Sci U S A. 2005. PMID: 16009937 Free PMC article.
-
Disruption of glucose homeostasis and induction of insulin resistance by elevated free fatty acids in human L02 hepatocytes.J Endocrinol Invest. 2009 May;32(5):454-9. doi: 10.1007/BF03346485. Epub 2009 Apr 29. J Endocrinol Invest. 2009. PMID: 19494713
-
Sex-dependent adipose glucose partitioning by the mitochondrial pyruvate carrier.bioRxiv [Preprint]. 2024 May 14:2024.05.11.593540. doi: 10.1101/2024.05.11.593540. bioRxiv. 2024. Update in: Mol Metab. 2024 Oct;88:102005. doi: 10.1016/j.molmet.2024.102005. PMID: 38798427 Free PMC article. Updated. Preprint.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
